Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $63 from $69 and keeps an Overweight rating on the shares. The firm notes Moderna laid out growth plans driven by mNEXSPIKE in 2026; mRNA-1010, intismeran and European growth in 2027; and mRNA-1083 and mRNA-1403 in 2028. Piper projects product sales of $1.73B in 2025 to grow to $2.15B in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Cautious Hold on Moderna Amid Strategic Pipeline Shift and Financial Uncertainty
- Moderna’s Strategic Growth and Financial Outlook: Buy Rating Affirmed by Analyst David Dai
- Moderna’s Ambitious Growth Plans and Financial Complexities Lead to Hold Rating
- Moderna’s Strategic Shift and Financial Outlook: A Hold Rating Amid Cautious Optimism
- Cautious Outlook on Moderna: Hold Rating Amid Breakeven Challenges and Pipeline Prospects